پتانسیل درمانی ویروس‌های انکولیتیک در درمان سرطان ریه ناشی از عوامل شیمیایی جنگی

1. Security SS-cotBHSttMoH. Report on Mustard Gas Experiments (Glasgow and London). 1943. Homeopathy: the journal of the Faculty of Homeopathy. 2011;100(1-2):27-35. 2. McClintock SD, Till GO, Smith MG, Ward PA. Protection from half‐mustard‐gas‐induced acute lung injury in the rat. Journal of Applied Toxicology: An International Journal. 2002;22(4):257-62. 3. Illig L, Paul E, Eyer P, Weger N, Born W. Treatment of psoriasis vulgaris with external sulfur mustard gas with particular reference to its potential carcinogenic risk. III. Clinical and experimental studies on the extent of percutaneous and inhalational uptake of sulfur mustard gas. Zeitschrift fur Hautkrankheiten. 1979;54(21):941-51.. 4. Saleh P, Bastani P, Piri R, Goldust M, Naghavi-Behzad M. Antimicrobial prophylaxis for surgical site infections in surgical wards in Northwest Iran. Life Science Journal. 2013;10(2):1977-81. 5. Stuart JA, Ursano RJ, Fullerton CS, Norwood AE, Murray K. Belief in exposure to terrorist agents: reported exposure to nerve or mustard gas by Gulf War veterans. The Journal of nervous and mental disease. 2003;191(7):431-6. 6. Azizi F, Jalali N, Nafarabadi M. The effect of chemical weapons on serum concentrations of various hormones. Iran J Med Sci. 1989;14:46-50. 7. Zarchi K, Akbar A, Naieni KH. Long-term pulmonary complications in combatants exposed to mustard gas: a historical cohort study. International journal of epidemiology. 2004;33(3):579-81. 8. Somani S, Dube S. Endurance training changes central and peripheral responses to physostigmine. Pharmacology Biochemistry and Behavior. 1992;41(4):773-81. 9. Ghanei M, Amini Harandi A. The respiratory toxicities of mustard gas. Iranian Journal of Medical Sciences. 2010;35(4):273-80. 10. Akhavan A, Ajalloueyan M, Ghanei M, Moharamzad Y. Late laryngeal findings in sulfur mustard poisoning. Clinical Toxicology. 2009;47(2):142-4. 11. Balali-Mood M, Afshari R, Zojaji R, Kahrom H, Kamrani M, Attaran D, et al. Delayed toxic effects of sulfur mustard on respiratory tract of Iranian veterans. Human & experimental toxicology. 2011;30(9):1141-9. 12. Amini M, Oghabian Z. Late-onset radiologic findings of respiratory system following sulfur mustard exposure. Asia Pacific Journal of Medical Toxicology. 2013;2(2):58-62. 13. Razavi SM, Salamati P, Harandi AA, Ghanei M. Prevention and treatment of respiratory consequences induced by sulfur mustard in Iranian casualties. International journal of preventive medicine. 2013;4(4):383. 14. Gao X, Anderson DR, Brown AW, Lin H, Amnuaysirikul J, Chua AL, et al. Pathological studies on the protective effect of a macrolide antibiotic, roxithromycin, against sulfur mustard inhalation toxicity in a rat model. Toxicologic pathology. 2011;39(7):1056-64. 15. Abtahi H, Peiman S, Foroumandi M, Safavi E. Long term follow-up of sulfur mustard related bronchiolitis obliterans treatment. Acta Medica Iranica. 2016:605-9. 16. Weinberger B, Laskin JD, Sunil VR, Sinko PJ, Heck DE, Laskin DL. Sulfur mustard-induced pulmonary injury: therapeutic approaches to mitigating toxicity. Pulmonary pharmacology & therapeutics. 2011;24(1):92-9. 17. Sadowska AM, Verbraecken J, Darquennes K, De Backer W. Role of N-acetylcysteine in the management of COPD. International journal of chronic obstructive pulmonary disease. 2006;1(4):425. 18. Tan DS-W, Gerlinger M, Teh B-T, Swanton C. Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. European Journal of Cancer. 2010;46(12):2166-77. 19. Lee JG, Wu R. Combination erlotinib-cisplatin and Atg3-mediated autophagy in erlotinib resistant lung cancer. PloS one. 2012;7(10):e48532. 20. Carter CA, Giaccone G. Treatment of non small cell lung cancer: overcoming the resistance to EGFR inhibitors. Current opinion in oncology. 2012;24(2):123. 21. Chen NG, Szalay AA, Buller RML, Lauer UM. Oncolytic viruses. Hindawi; 2012. 22. Bauzon M, Hermiston TW. Oncolytic viruses: the power of directed evolution. Advances in virology. 2012;2012. 23. Auer R, Bell JC. Oncolytic viruses: smart therapeutics for smart cancers. Future Oncology. 2012;8(1):1-4. 24. Kottke T, Errington F, Pulido J, Galivo F, Thompson J, Wongthida P, et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nature medicine. 2011;17(7):854-9. 25. Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, et al. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Human gene therapy. 2011;22(11):1343-53. 26. Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, et al. Potentiating cancer immunotherapy using an oncolytic virus. Molecular Therapy. 2010;18(8):1430-9. 27. Brun J, Mahoney DJ, Le Boeuf F, Lefebvre C, Sanaei CA, Falls T, et al. Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum. International journal of cancer. 2013;132(3):726-31. 28. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. The Journal of Pathology: A Journal of the Pathological Society of Great Britain and Ireland. 2006;208(2):299-318. 29. Alvarez-Breckenridge C, Kaur B, Chiocca EA. Pharmacologic and chemical adjuvants in tumor virotherapy. Chemical reviews. 2009;109(7):3125-40. 30. Decoster L, Wauters I, Vansteenkiste J. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Annals of oncology. 2012;23(6):1387-93. 31. Stojdl DF, Lichty BD, Paterson JM, Power AT, Knowles S, Marius R, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer cell. 2003;4(4):263-75. 32. Fukazawa T, Maeda Y, Matsuoka J, Ono T, Mominoki K, Yamatsuji T, et al. Targeting KRAS Mutation-bearing Lung Cancer In Vivo by Pulmonary Surfactant–Adenovirus-mediated Gene Transfer. Anticancer research. 2010;30(12):4925-35. 33. Zhang J-F, Wei F, Wang H-P, Li H-M, Qiu W, Ren P-K, et al. Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. Journal of Experimental & Clinical Cancer Research. 2010;29(1):1-7. 34. Oh JY, Park MY, Kim DR, Lee JH, Shim S-H, Chung J-H, et al. Combination gene therapy of lung cancer with conditionally replicating adenovirus and adenovirus-herpes simplex virus thymidine kinase. International journal of molecular medicine. 2010;25(3):369-76. 35. Yao F, Murakami N, Bleiziffer O, Zhang P, Akhrameyeva NV, Xu X, et al. Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy. Journal of virology. 2010;84(16):8163-71. 36. Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer research. 2012;72(10):2609-21. 37. Meng S, Zhou Z, Chen F, Kong X, Liu H, Jiang K, et al. Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer letters. 2012;317(1):56-64. 38. Rudin CM, Poirier JT, Senzer NN, Stephenson J, Loesch D, Burroughs KD, et al. Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. Clinical Cancer Research. 2011;17(4):888-95. 39. Gujar SA, Marcato P, Pan D, Lee PW. Reovirus virotherapy overrides tumor antigen presentation evasion and promotes protective antitumor immunity. Molecular cancer therapeutics. 2010;9(11):2924-33. 40. Sei S, Mussio JK, Yang Q-e, Nagashima K, Parchment RE, Coffey MC, et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Molecular cancer. 2009;8(1):1-15. 41. Nguyen TL-A, Wilson MG, Hiscott J. Oncolytic viruses and histone deacetylase inhibitors—a multi-pronged strategy to target tumor cells. Cytokine & growth factor reviews. 2010;21(2-3):153-9. 42. Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proceedings of the National Academy of Sciences. 2010;107(4):1576-81. 43. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proceedings of the National Academy of Sciences. 2006;103(34):12873-8. 44. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM, et al. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clinical Cancer Research. 2008;14(1):259-69. 45. Wodarz D. Use of oncolytic viruses for the eradication of drug-resistant cancer cells. Journal of The Royal Society Interface. 2009;6(31):179-86. 46. Neschadim A, Wang J, Lavie A, Medin J. Bystander killing of malignant cells via the delivery of engineered thymidine-active deoxycytidine kinase for suicide gene therapy of cancer. Cancer gene therapy. 2012;19(5):320-7. 47. Porosnicu M, Mian A, Barber GN. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer research. 2003;63(23):8366-76. 48. Adusumilli PS, Stiles BM, Chan M-K, Chou T-C, Wong RJ, Rusch VW, et al. Radiation therapy potentiates effective oncolytic viral therapy in the treatment of lung cancer. The Annals of thoracic surgery. 2005;80(2):409-17. 49. Touchefeu Y, Vassaux G, Harrington KJ. Oncolytic viruses in radiation oncology. Radiotherapy and Oncology. 2011;99(3):262-70. 50. Heise C, Sampson-Johannes A, Williams A, Mccormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nature medicine. 1997;3(6):639-45. 51. You L, Yang C-T, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. Can 52. Cai Y, Liu X, Huang W, Zhang K, Liu X-y. Synergistic antitumor effect of TRAIL and IL-24 with complete eradication of hepatoma in the CTGVT-DG strategy. Acta Biochim Biophys Sin. 2012;44(6):535-43. 53. Zhong S, Yu D, Wang Y, Qiu S, Wu S, Liu XY. An armed oncolytic adenovirus ZD55-IL-24 combined with ADM or DDP demonstrated enhanced antitumor effect in lung cancer. Acta Oncologica. 2010;49(1):91-9. 54. Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, et al. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PloS one. 2012;7(2):e31085. 55. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset F-L, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Research. 2000;60(6):1492-7. 56. Simpson GR, Han Z, Liu B, Wang Y, Campbell G, Coffin RS. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Research. 2006;66(9):4835-42. 57. Shanker M, Willcutts D, Roth JA, Ramesh R. Drug resistance in lung cancer. Lung Cancer: Targets and Therapy. 2010;1:23. 58. Müller LM, Holmes M, Michael JL, Scott GB, West EJ, Scott KJ, et al. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21. Journal for immunotherapy of cancer. 2019;7(1):1-16. 59. Müller LM, Migneco G, Scott GB, Down J, King S, Askar B, et al. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for immunotherapy of cancer. 2021;9(3). 60. Biotherapeutics J. A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma. ClinicalTrials gov: NCT00429312, First Posted: Jan. 2007;31. 61. Morelli MP, Xie C, Brar G, Floudas CS, Fioravanti S, Walker M, et al. A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report. American Society of Clinical Oncology; 2019. 62. Biologics V. Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.(1716-12) ClinicalTrials. gov. 2018.